ENSC 2.15 ▼ -0.92% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Ensysce Biosciences Inc.

    NASDAQ: ENSC · Real-Time Price · USD
    2.15
    -0.02 (-0.92%)
    At close: Sep 04, 2025, 3:49 PM
    2.14
    -0.47%
    After-hours: Sep 04, 2025, 04:10 PM EDT
    -0.92%
    Bid 2.09
    Market Cap 5.1M
    Revenue (ttm) 7.41M
    Net Income (ttm) -6.58M
    EPS (ttm) -3.51
    PE Ratio (ttm) -0.61
    Forward PE -42
    Analyst n/a
    Ask 2.14
    Volume 63,214
    Avg. Volume (20D) 338,750
    Open 2.20
    Previous Close 2.17
    Day's Range 2.10 - 2.21
    52-Week Range 1.62 - 14.67
    Beta 1.02

    About ENSC

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ENSC
    Website n/a
    Full Company Profile

    Next Earnings Release

    Ensysce Biosciences Inc. is scheduled to release its earnings on Nov 11, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 month ago
    +0.48%
    ENSC stock has given up its prior gain. Ensysce Bi... Unlock content with Pro Subscription
    1 month ago
    +0.48%
    Ensysce Biosciences shares are trading higher after the company announced it received FDA feedback for PF614-MPAR.
    news image

    2 hours ago · accessnewswire.com

    Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium

    ~ Experts Spotlight TAAP™ and MPAR® as Next-Generation Solutions for Severe Pain ~ SAN DIEGO, CA / ACCESS Newswire / September 4, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Comp...

    news image

    2 weeks ago · accessnewswire.com

    Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025

    ~ The Summit is the Premier Industry Event for Defining How New Product Planning Teams and Related Functions Make Informed, Value-Based, Data-Driven Decisions ~ ~ Ensysce Biopharma Leader to Deliver O...

    news image

    3 weeks ago · accessnewswire.com

    Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

    Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory Approval Receives $5.3 Million Installment from NIDA To Support Overdose Prot...

    news image

    1 month ago · accessnewswire.com

    Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback

    ~ Productive FDA Meeting Highlights Path Toward Overdose Protection Labeling and 505(b)(2) Regulatory Strategy ~ ~ FDA and Ensysce Aligned on Collaborative Approach to Ensure Product's Full Safety Ben...

    news image

    1 month ago · accessnewswire.com

    Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse

    ~ FDA Protocol Review Completed ~ ~ Rho, Inc. Selected as Clinical Research Partner ~ SAN DIEGO, CA / ACCESS Newswire / July 16, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Compa...

    news image

    2 months ago · accessnewswire.com

    Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

    ~ Treatment to Evaluate Effect of Food on Overdose Protection of MPAR ~ ~ Grant Funds from NIDA Accelerating Clinical Development Program ~ SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 24, 2025 / En...

    news image

    2 months ago · accessnewswire.com

    Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

    ~ Pain Management, RE-Invented: A New Era for Analgesia ~ SAN DIEGO, CA / ACCESS Newswire / June 11, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharm...

    news image

    3 months ago · accessnewswire.com

    Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

    ~ PF614-MPAR Moving to Next Stage of Development, Finalizing Drug Formulation ~ ~ Funds Accelerate Path Towards Commercialization ~ SAN DIEGO, CA / ACCESS Newswire / June 4, 2025 / Ensysce Biosciences...

    Add to Watchlist